Genentech: Baris Bingol
Por um escritor misterioso
Descrição
I am proud to be part of the scientific team at Genentech that values scientific excellence above all to fuel therapeutic programs for patients in need.
Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies: Molecular Therapy - Nucleic Acids
Bay Area Molecular Neuroscience Meeting – July 20th, 2018 – UC Berkeley
Baris BINGOL, Genentech, California, Department of Neuroscience
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study - The Lancet Neurology
Genentech: Baris Bingol
Swetha Chandrasekar on LinkedIn: Life update! This week, I moved out to the Bay Area and started a new…
The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy
PPEF2 Opposes PINK1-Mediated Mitochondrial Quality Control by Dephosphorylating Ubiquitin - ScienceDirect
A Multifaceted Hit-Finding Approach Reveals Novel LC3 Family Ligands
Ubiquilin1 promotes antigen-receptor mediated proliferation by eliminating mislocalized mitochondrial proteins
Ubiquilin1 promotes antigen-receptor mediated proliferation by eliminating mislocalized mitochondrial proteins
Baris Bingol's Instagram, Twitter & Facebook on IDCrawl
Genentech: Christian Cunningham Senior Principal Scientist, Early Discovery Biochemistry, and Director, Peptide Therapeutics
